OKYO OKYO Pharma Inc: Prakiraan wutah bathi resik saben saham kanggo taun ngarep

International patent protection is critical for OKYO Pharma Limited (OKYO) due to geopolitical risks associated with drug registration. The brand's success relies on the launch of anti-inflammatory drops for patients with "dry eye," and analyst expectations for N+1 profit dynamics on GURU.Markets indicate that the metric level is -200.50. Currently, OKYO Pharma Limited (OKYO) is systematically spending investor capital on clinical trials in the complete absence of revenue.
Rincian metrik lan analitis perusahaan OKYO Pharma Limited (OKYO)

This indicator measures the consensus earnings forecast for the upcoming period, isolating the long-term fundamental trend from market noise. The current value of -200.50 in the next year's EPS projections for OKYO Pharma Limited (OKYO) reflects market expectations regarding the commercialization of the OK-101 drug for the therapy of neuropathic pain. The positive trajectory of this metric signals capital's readiness to invest in a unique non-hormonal treatment mechanism for ophthalmological pathologies.